Immunotherapy drug shows promise for tough bile duct cancer
NCT ID NCT02829918
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 33 times
Summary
This study tested the drug nivolumab in 54 people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder) that had not responded to prior chemotherapy. The goal was to see if nivolumab could shrink tumors or slow the cancer's growth. Nivolumab is an immunotherapy that helps the immune system attack cancer cells, but it is not yet approved for this type of cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Cancer Center
Duarte, California, 91010, United States
-
Emory University Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.